epcoritamab

💊Medication

Generic name

Epcoritamab-Bysp

Brand names

Epkinly

Drug class

Bispecific CD20-directed CD3 T Cell Engager, CD20-directed Antibody Interactions, CD3-directed Antibody Interactions, CD3 Receptor Agonists, Cytochrome P450 Inhibitors

Route

Subcutaneous

Type

Human Prescription Drug

Manufacturer

Genmab US, Inc.

Indications: 1 INDICATIONS AND USAGE EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphom… (per FDA label)

• PHASE1ACTIVE_NOT_RECRUITING
  Epcoritamab in Chronic Lymphocytic Leukemia and Richter SyndromeNational Heart, Lung, and Blood Institute (NHLBI) · NCT06676033
• PHASE2RECRUITING
  Epco, Zanu, Ritux for R/R FL or MZLReid Merryman, MD · NCT06563596
• PHASE3RECRUITING
  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaGenmab · NCT06191744
• PHASE1/PHASE2RECRUITING
  Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLStichting Hemato-Oncologie voor Volwassenen Nederland · NCT05791409
• PHASE2RECRUITING
  Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington · NCT07097363
• PHASE2RECRUITING
  Epcoritamab and Rituximab for First-line Follicular LymphomaReid Merryman, MD · NCT05783609

via ClinicalTrials.gov

Wikidata facts

Instance of

monoclonal antibody

via Wikidata · CC0